BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28978336)

  • 1. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
    He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
    Yu C; Chen S; Guo Y; Sun C
    Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic gene TRIM10 confers resistance to cisplatin in osteosarcoma cells and activates the NF-κB signaling pathway.
    Xi X; Bao Y; Zhou Y; Chen Y; Zhong X; Liao J; Zhou J; Xu S; Cao Z; Hu K; Hu Y; He X; Zhou L; Lin H; Wu Q
    Cell Biol Int; 2021 Jan; 45(1):74-82. PubMed ID: 32997424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.
    Tan G; Xie B; Yu N; Huang J; Zhang B; Lin F; Li H
    Int J Clin Oncol; 2021 Mar; 26(3):532-542. PubMed ID: 33387087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
    Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
    Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-κB signaling pathway.
    Wang L; Zhou W; Zhong Y; Huo Y; Fan P; Zhan S; Xiao J; Jin X; Gou S; Yin T; Wu H; Liu T
    Mol Cancer; 2017 Mar; 16(1):61. PubMed ID: 28288630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
    Ito Y; Kikuchi E; Tanaka N; Kosaka T; Suzuki E; Mizuno R; Shinojima T; Miyajima A; Umezawa K; Oya M
    BMC Cancer; 2015 Apr; 15():324. PubMed ID: 25926105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
    Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
    Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
    Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
    Yang G; Xiao X; Rosen DG; Cheng X; Wu X; Chang B; Liu G; Xue F; Mercado-Uribe I; Chiao P; Du X; Liu J
    Clin Cancer Res; 2011 Apr; 17(8):2181-94. PubMed ID: 21339307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
    Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
    Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
    Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
    J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF-κB Signaling.
    Mon MT; Yodkeeree S; Punfa W; Pompimon W; Limtrakul P
    Chem Pharm Bull (Tokyo); 2018; 66(2):162-169. PubMed ID: 29386467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy.
    Meng J; Liu K; Shao Y; Feng X; Ji Z; Chang B; Wang Y; Xu L; Yang G
    Cell Death Dis; 2020 Feb; 11(2):137. PubMed ID: 32080166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling.
    Jiang L; Ren L; Zhang X; Chen H; Chen X; Lin C; Wang L; Hou N; Pan J; Zhou Z; Huang H; Huang D; Yang J; Liang Y; Li J
    EBioMedicine; 2019 May; 43():188-200. PubMed ID: 30979686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.